Outlook Therapeutics (OTLK) announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general corporate purposes. BTIG is acting as sole book-running manager for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics price target lowered to $8 from $10 at Guggenheim
- Biotech Alert: Searches spiking for these stocks today
- Outlook Therapeutics reports Q2 EPS (40c), consensus (55c)
- Outlook Therapeutics Approves Retention Incentive for CFO
- Outlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010